We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.8%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.77B
AUM Growth
+$591M
(+27%)
Cap. Flow
+$347M
Cap. Flow
% of AUM
12.51%
Top 10 Holdings %
Top 10 Hldgs %
59.71%
Holding
55
New
19
Increased
10
Reduced
9
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$108M |
| 2 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$105M |
| 3 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$84M |
| 4 |
Cardinal Health
CAH
|
+$81.8M |
| 5 |
HOLX
Hologic
HOLX
|
+$74.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$115M |
| 2 |
AET
Aetna Inc
AET
|
+$95.4M |
| 3 |
Merck
MRK
|
+$93.7M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$77.9M |
| 5 |
Align Technology
ALGN
|
+$60.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.65% |
| 2 | Financials | 4.93% |
| 3 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLVS
26
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $32.8M | 1.18% |
+350,000
| New | +$21.4M |
|
|
ESRX
27
CALL
DELISTED
Express Scripts Holding Company
ESRX
| $31.9M | 1.15% |
+500,000
| New | +$31.4M |
|
28
CALL
Bristol-Myers Squibb
BMY
$133B
| $27.9M | 1.01% |
+500,000
| New | +$27.2M |
|
29
Eli Lilly
LLY
$1.02T
| $26.9M | 0.97% |
+327,064
| New | +$26.7M |
|
30
LivaNova
LIVN
$4.41B
| $24.5M | 0.88% |
+400,000
| New | +$22.6M |
|
|
CLVS
31
DELISTED
Clovis Oncology, Inc.
CLVS
| $23.1M | 0.83% |
246,300
-53,700
| -18% | -$3.29M |
|
32
UnitedHealth
UNH
$381B
| $19.1M | 0.69% |
103,100
-71,900
| -41% | -$12.6M |
|
33
Medtronic
MDT
$109B
| $14.9M | 0.54% |
167,430
-45,600
| -21% | -$3.85M |
|
34
Puma Biotechnology
PBYI
$397M
| $13.1M | 0.47% |
+150,000
| New | +$8.39M |
|
35
Boston Scientific
BSX
$67.9B
| $12.6M | 0.45% |
+453,950
| New | +$12M |
|
|
VAR
36
PUT
DELISTED
Varian Medical Systems, Inc.
VAR
| $10.3M | 0.37% |
+100,000
| New | +$9.63M |
|
|
HRC
37
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $9.95M | 0.36% |
+125,000
| New | +$9.44M |
|
38
Zoetis
ZTS
$32.2B
| $5.76M | 0.21% |
92,334
-607,666
| -87% | -$35.9M |
|
39
Baxter International
BAX
$13.5B
| $3.97M | 0.14% |
65,610
-609,390
| -90% | -$34.6M |
|
|
40
Align Technology
ALGN
$12.1B
| – | – |
-525,000
| Closed | -$60.2M |
|
41
Becton Dickinson
BDX
$45.5B
| – | – |
-25,174
| Closed | -$4.5M |
|
42
Cigna
CI
$74.9B
| – | – |
-100,720
| Closed | -$14.8M |
|
43
Quest Diagnostics
DGX
$25.9B
| – | – |
-78,982
| Closed | -$7.75M |
|
44
DexCom
DXCM
$31.9B
| – | – |
-900,000
| Closed | -$19.1M |
|
45
HCA Healthcare
HCA
$86.8B
| – | – |
-325,000
| Closed | -$28.9M |
|
46
Medpace
MEDP
$15.9B
| – | – |
-700,000
| Closed | -$20.9M |
|
|
47
Merck
MRK
$323B
| – | – |
-1,545,800
| Closed | -$93.7M |
|
48
Qiagen
QGEN
$8.52B
| – | – |
-1,650,347
| Closed | -$50.7M |
|
|
SYNH
49
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| – | – |
-1,700,000
| Closed | -$77.9M |
|
|
ALXN
50
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-950,000
| Closed | -$115M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2017 Portfolio in Review
As of Q2 2017, HealthCor Management held 55 positions worth $2.77B, up 27% from $2.18B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
HealthCor Management deployed $347M of net new capital in Q2 2017, opening 19 new positions and adding to 10 existing holdings. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 2,402,350 shares worth $108M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Financials and Materials.
On the sell side, the largest reduction was Aetna Inc, an estimated $95.4M trimmed.
- HealthCor Management's largest Q2 2017 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 2,402,350 shares worth $108M.
- HealthCor Management added most to Danaher in Q2 2017, an estimated $108M increase.
- HealthCor Management's biggest Q2 2017 reduction was Aetna Inc, cutting an estimated $95.4M.
- HealthCor Management fully exited Alexion Pharmaceuticals in Q2 2017, selling an estimated $115M.
- HealthCor Management's ten largest holdings make up 60% of its $2.77B portfolio in Q2 2017.
- HealthCor Management opened 19 new positions and closed 16 in Q2 2017.
- HealthCor Management's portfolio value rose 27% quarter-over-quarter to $2.77B.
Based on HealthCor Management's 13F filing for Q2 2017, filed 14 Aug 2017.